These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 8525368)

  • 21. Design and synthesis of chiral and racemic phosphonate-based haptens for the induction of aldolase catalytic antibodies.
    Mu YQ; Gibbs RA
    Bioorg Med Chem; 1997 Jul; 5(7):1327-37. PubMed ID: 9377093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic and fluorescence studies of affinity maturation in related antibodies.
    Pauyo T; Hilinski GJ; Chiu PT; Hansen DE; Choi YJ; Ratner DI; Shah-Mahoney N; Southern CA; O'Hara PB
    Mol Immunol; 2006 Mar; 43(7):812-21. PubMed ID: 16137768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural basis for antibody catalysis of a disfavored ring closure reaction.
    Gruber K; Zhou B; Houk KN; Lerner RA; Shevlin CG; Wilson IA
    Biochemistry; 1999 Jun; 38(22):7062-74. PubMed ID: 10353817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isomer activation controls stereospecificity of class I fructose-1,6-bisphosphate aldolases.
    Heron PW; Sygusch J
    J Biol Chem; 2017 Dec; 292(48):19849-19860. PubMed ID: 28972169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aldol sensors for the rapid generation of tunable fluorescence by antibody catalysis.
    List B; Barbas CF; Lerner RA
    Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15351-5. PubMed ID: 9860972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Charge stabilization and entropy reduction of central lysine residues in fructose-bisphosphate aldolase.
    St-Jean M; Blonski C; Sygusch J
    Biochemistry; 2009 Jun; 48(21):4528-37. PubMed ID: 19354220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reaction properties of catalytic antibodies encapsulated in organo substituted SiO2 sol-gel materials.
    Kato K; Saito T; Seelan S; Tomita M; Yokogawa Y
    J Biosci Bioeng; 2005 Oct; 100(4):478-80. PubMed ID: 16310742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breaking the Dogma of Aldolase Specificity: Simple Aliphatic Ketones and Aldehydes are Nucleophiles for Fructose-6-phosphate Aldolase.
    Roldán R; Sanchez-Moreno I; Scheidt T; Hélaine V; Lemaire M; Parella T; Clapés P; Fessner WD; Guérard-Hélaine C
    Chemistry; 2017 Apr; 23(21):5005-5009. PubMed ID: 28266745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and syntheses of three haptens to generate catalytic antibodies that cleave amide bonds with nucleophilic catalysis.
    Ersoy O; Fleck R; Blanco MJ; Masamune S
    Bioorg Med Chem; 1999 Feb; 7(2):279-86. PubMed ID: 10218819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody catalysis of a reaction otherwise strongly disfavoured in water.
    Shabat D; Itzhaky H; Reymond JL; Keinan E
    Nature; 1995 Mar; 374(6518):143-6. PubMed ID: 7877686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sweet siblings with different faces: the mechanisms of FBP and F6P aldolase, transaldolase, transketolase and phosphoketolase revisited in light of recent structural data.
    Tittmann K
    Bioorg Chem; 2014 Dec; 57():263-280. PubMed ID: 25267444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tech.Sight. Antibody design by man and nature.
    Wentworth P
    Science; 2002 Jun; 296(5576):2247-9. PubMed ID: 12077422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A bait and switch hapten strategy generates catalytic antibodies for phosphodiester hydrolysis.
    Wentworth P; Liu Y; Wentworth AD; Fan P; Foley MJ; Janda KD
    Proc Natl Acad Sci U S A; 1998 May; 95(11):5971-5. PubMed ID: 9600901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure of a fructose-1,6-bis(phosphate) aldolase liganded to its natural substrate in a cleavage-defective mutant at 2.3 A(,).
    Choi KH; Mazurkie AS; Morris AJ; Utheza D; Tolan DR; Allen KN
    Biochemistry; 1999 Sep; 38(39):12655-64. PubMed ID: 10504235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.
    Popkov M; Rader C; Gonzalez B; Sinha SC; Barbas CF
    Int J Cancer; 2006 Sep; 119(5):1194-207. PubMed ID: 16570283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence of a catalytic tetrad during evolution of a highly active artificial aldolase.
    Obexer R; Godina A; Garrabou X; Mittl PR; Baker D; Griffiths AD; Hilvert D
    Nat Chem; 2017 Jan; 9(1):50-56. PubMed ID: 27995916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toward selective covalent inactivation of pathogenic antibodies: a phosphate diester analog of vasoactive intestinal peptide that inactivates catalytic autoantibodies.
    Nishiyama Y; Bhatia G; Bangale Y; Planque S; Mitsuda Y; Taguchi H; Karle S; Paul S
    J Biol Chem; 2004 Feb; 279(9):7877-83. PubMed ID: 14676184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldolase antibody activation of prodrugs of potent aldehyde-containing cytotoxics for selective chemotherapy.
    Sinha SC; Li LS; Watanabe S; Kaltgrad E; Tanaka F; Rader C; Lerner RA; Barbas CF
    Chemistry; 2004 Oct; 10(21):5467-72. PubMed ID: 15378729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of the hapten for the induction of antibodies catalyzing aldol reaction.
    Teraishi K; Saito M; Fujii I; Nakamura H
    J Mol Graph; 1994 Dec; 12(4):282-5, 292. PubMed ID: 7696219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of the Schiff base forming fructose-1,6-bisphosphate aldolase: structural analysis of reaction intermediates.
    Lorentzen E; Siebers B; Hensel R; Pohl E
    Biochemistry; 2005 Mar; 44(11):4222-9. PubMed ID: 15766250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.